Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse. Some states that have passed recreational or medical marijuana legislation are still negotiating the details for implementing these programs. in 2002 to 49.2%

Recreational 52

Recreational Data Cannabis DEA 52

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. The MDMA Therapy Training Program was created to train the next generation of psychedelic therapists. Lyle Craker, Ph.D., Reddit awarded $82,765.95 MAPS Founder Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JULY 9, 2021

Drug Enforcement Agency (“DEA”). Some physicians and therapists have argued that the Right to Try Act permits them to administer psilocybin to terminally ill patients (since studies are well past the Phase 1 stage), but the DEA has met this with resistance given psilocybin’s status as a Schedule I drug. AIMS Institute, PLLC.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2, 2002 , 116 Stat. 2, 2002 , 116 Stat. 2(a), Oct. 21, 1998 , 112 Stat. 2681–759 ; Pub. 611 ; Pub.

Banking 45

Banking Law Marijuana State Laws 45